Genmab AS (GMAB : NASDAQ)
Common Stock
$36.89
USD
+0.32 (0.88%)
Last updated: 2026-10-14
Follow GMAB
GMAB
Genmab AS
WealthAwesomePerformance
1 Day
+0.88%
1 Week
+0.65%
1 Month
+12.99%
YTD
+15.93%
Key Statistics
Market Cap
$22.68B
52W High
$40.17
52W Low
$23.62
P/E Ratio
29.05
50 Day MA
$33.84
200 Day MA
$29.79
Beta
0.65
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/14/2026 | $36.38 | $37.24 | $36.13 | $36.89 | $36.89 | 2,687,385 |
| 10/13/2026 | $37.23 | $37.35 | $36.34 | $36.57 | $36.57 | 3,736,922 |
| 10/12/2026 | $37.18 | $37.71 | $36.94 | $37.37 | $37.37 | 3,126,354 |
| 10/9/2026 | $36.55 | $37.15 | $36.33 | $37.07 | $37.07 | 2,333,400 |
| 10/8/2026 | $36.17 | $36.28 | $35.09 | $36.05 | $36.05 | 4,299,492 |
| 10/7/2026 | $37.28 | $37.87 | $36.27 | $36.65 | $36.65 | 4,253,684 |
| 10/6/2026 | $39.11 | $39.15 | $37.07 | $37.80 | $37.80 | 6,595,862 |
| 10/5/2026 | $35.09 | $40.17 | $35.02 | $38.48 | $38.48 | 12,403,391 |
| 10/2/2026 | $34.39 | $35.02 | $33.73 | $34.75 | $34.75 | 5,436,400 |
| 10/1/2026 | $35.25 | $35.80 | $34.52 | $34.55 | $34.55 | 6,377,000 |
Analyst Price Targets
Based on 12 analysts covering GMAB · as of Oct 14, 2026
Wall Street analysts forecast GMAB stock price to rise 20.4% over the next 12 months.
Consensus
Strong Buy4.75 / 5.00
Avg. Target
US$44.40
+20.4% Upside
Previously US$44.13 on Oct 12, 2026
Current Price
US$36.89
Last close
Analyst Breakdown (12 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GMAB's historical volatility
30-Day Vol
40.7%
Annualized
90-Day Vol
33.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
US$44.10
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$39.15 | US$34.02 – US$45.06 |
| 60 trading days | US$41.55 | US$34.06 – US$50.69 |
| 90 trading days | US$44.10 | US$34.57 – US$56.26 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Genmab AS
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Financials
- Revenue (TTM)
- $4.13B
- EBITDA
- $1.38B
- Profit Margin
- 19.08%
- ROE (TTM)
- 14.00%
- EPS (Diluted)
- 1.27
- Book Value
- 9.98
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About GMAB.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| NVNI | Nvni Group Limited Ordinary Shares | $0.53 | +382.56% |
| HVII | Hennessy Capital Investment Corp. VII Ordinary Shares | $4.46 | +150.56% |
| SOBR | Sobr Safe Inc | $0.08 | +94.88% |
| GLND | Greenland Energy Company Common Stock | $3.90 | +76.47% |
| TGL | Treasure Global Inc. | $0.45 | +61.87% |
| NIVF | NewGenIvf Group Limited Class A Ordinary Shares | $0.29 | +50.20% |
| CRANR | Crane Harbor Acquisition Corp. II Rights | $0.16 | +45.47% |
| HCICR | Hennessy Capital Investment Corp. VIII Share Rights | $0.12 | +41.53% |
GMAB.US news timeline
2 articles covering GMAB.US, most recent first
Latest